Sunday, March 11, 2018
PSMA targeted therapies, information about
01. German PSMA theraputics .here. Ligands for Imaging and Therapy
02. Google search on psma ligand .here.
other things to engage PSMA receptors in the salivary glands, possibly?
03. 2017 Review article, Japan, alpha particle therapy .here.
04. Trial NCT03276572 Cornell, Weil, NYC, Dr.Tagawa 225Ac
91. NCT02913196 - apalutamide trial in MCRPC & chemo
==GERMANY Treatment Heidelberg 177Lu==
Treatment: alpha particles + PSMA, PubMed article .here.
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
clemens.kratochwil@med.uni-heidelberg.de
University Hospital Heidelberg ( .here. ) Markus Hohenfellner, M.D.
Subscribe to:
Post Comments (Atom)
01 excerpt:
ReplyDeleteSubsequently, high affinity antibodies directed against extracellular epitopes of PSMA have been developed, such as J415, J533, and J591 [28]. It was shown that 111In-J591 accurately targets bone and soft tissue metastatic PCa lesions [29] and that 177Lu-labeled J591 can be used safely in radioimmunotherapy (RIT) directed against micrometastatic PCa [30]. Major disadvantages limiting the use of radiolabeled monoclonal antibodies as theranostic radiopharmaceuticals are their relatively long circulatory half-life (3-4 days), poor tumor penetration, and low tumor-to-normal tissue ratios, especially at early time points. Small molecules, in contrast, exhibit rapid extravasation, rapid diffusion in the extravascular space, and faster blood clearance. This could result in high tumor-normal tissue contrast early after injection of the tracer.